Johnson & Johnson $JNJ Holdings Trimmed by Generate Investment Management Ltd

Generate Investment Management Ltd cut its stake in Johnson & Johnson (NYSE:JNJ) by 15.7% in the third quarter, HoldingsChannel reports. The fund owned 93,579 shares of the company’s stock after selling 17,386 shares during the period. Johnson & Johnson accounts for 1.0% of Generate Investment Management Ltd’s holdings, making the stock its 23rd largest position. Generate Investment Management Ltd’s holdings in Johnson & Johnson were worth $24,774,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of JNJ. First Citizens Bank & Trust Co. boosted its position in shares of Johnson & Johnson by 71.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 52,947 shares of the company’s stock worth $14,017,000 after purchasing an additional 22,136 shares during the last quarter. Citrine Capital LLC increased its holdings in Johnson & Johnson by 0.5% in the third quarter. Citrine Capital LLC now owns 10,523 shares of the company’s stock valued at $2,786,000 after purchasing an additional 55 shares during the last quarter. My Personal CFO LLC lifted its stake in Johnson & Johnson by 2.5% in the third quarter. My Personal CFO LLC now owns 4,326 shares of the company’s stock valued at $1,145,000 after buying an additional 105 shares during the period. XY Planning Network Inc. lifted its stake in Johnson & Johnson by 11.2% in the third quarter. XY Planning Network Inc. now owns 6,932 shares of the company’s stock valued at $1,835,000 after buying an additional 698 shares during the period. Finally, Salem Investment Counselors Inc. boosted its holdings in Johnson & Johnson by 0.6% during the third quarter. Salem Investment Counselors Inc. now owns 177,339 shares of the company’s stock worth $46,949,000 after buying an additional 1,055 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.5%

Shares of JNJ traded up $3.85 on Wednesday, hitting $252.46. The company’s stock had a trading volume of 4,045,485 shares, compared to its average volume of 7,973,307. The firm’s fifty day moving average price is $265.89 and its 200-day moving average price is $249.37. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $608.39 billion, a price-to-earnings ratio of 29.25, a P/E/G ratio of 2.70 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the company posted $2.80 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.09 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 62.11%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on JNJ shares. Citigroup lifted their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $282.00 to $275.00 and set an “overweight” rating for the company in a research note on Wednesday. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a report on Wednesday. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, TD Cowen upped their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $273.61.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, ahead of the $2.53 consensus, while revenue rose 5.9% year over year to approximately $25.4 billion. Innovative Medicine revenue grew 7.9%, supported by oncology, immunology and strong TREMFYA sales. Johnson & Johnson Q3 Earnings Surpass Estimates
• Positive Sentiment: Management raised its 2026 outlook to revenue of $101.0 billion-$101.4 billion and adjusted EPS of $11.05-$11.15. The improved outlook and pharmaceutical growth provide fundamental support for the stock. Johnson & Johnson reports Q3 2026 results and raises guidance
• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating and set a $280 price target. Although the target was reduced from $290, it still implies meaningful upside from recent trading levels. Johnson & Johnson analyst coverage
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, maintaining JNJ’s appeal as a defensive income investment. Johnson & Johnson quarterly dividend announcement
• Neutral Sentiment: JNJ is reportedly considering a mid-2027 spinoff of its hips-and-knees orthopedics business. The move could sharpen the company’s focus, but its benefits and execution risks remain uncertain. J&J considers hips-and-knees spinoff
• Negative Sentiment: MedTech growth of roughly 2.5% missed expectations, with weakness in surgery and cardiovascular products, particularly outside the United States. Investors remain concerned that pharmaceutical strength is masking slower device-market performance.
• Negative Sentiment: Reported profit was sharply reduced by special charges tied to the proposed talc litigation resolution and recent business-development activity. Management also warned that new drug deals may weigh on 2027 earnings, while Erste Group lowered its FY2027 EPS estimate to $12.65 from $12.83.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.